Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
like that as sometimes you get a boost around 1pm, prefer that than RRL where the aussies open first. I swear they all still smashed from the Bar B
discount for doing a T20, they were this price back in July, an interesting scale for the last year as they look to have dipped prior to this slight rise
in about 3pm on friday, did a T20 got about 65000 shares.
the winner as well :-)
As I don't control the markets and I have invested on a hunch but there is evidence, may it dip to 1.75 before hitting 10p for you as then you will be the winner and I will be the good samaritan and not the ramper !!!
I guess all companies seem potentially good, this one seems prime to me, I think the comparison to PXS is relevant, would be very interesting if they are just to get a rather large contract with their fandango machine!! which helps with Warfarin. I don't seem to see much business outside of the USA but that is enough of a market. Will be interesting to see what happens on monday. Would be great for Gandalf's credibility to have sourced a potential good un
When you do make it to the board. This I found quite interesting, they paid all of the SP for their significant shareholding. Osmetech PLC (“Osmetech” or “the Company”) (AIM:OMH) announces that it was notified on 23 December 2009 that, following the placing at 2.05p per share announced on 21 December 2009, FMR LLC has a total interest of 147,133,039 ordinary 0.1p shares in the Company which represents approximately 9.01% of the issued share capital of the Company. The total number of issued ordinary 0.1p shares is 1,633,443,351. Osmetech does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in Osmetech is 1,633,443,351.
Their year end is 31-Dec which could be an indication on the investment which may be favourable. Perhaps results will be over expectation.
eSensor XT-8 system for warfarin sensitivity testing. The eSensor XT-8 system for warfarin sensitivity testing detects multiple genetic variations that identifies patients at risk for warfarin sensitivity and thus allows estimation of the optimal and safe warfarin dose. Submitter and manufacturer: Osmetech Molecular Diagnostics (Pasadena, CA; www.osmetech.com) Suppliers: Aubrey Group Inc. (Irvine, CA; www.aubreygroup.com); Aline Inc. (Redondo Beach, CA; www.alineinc.com) "The eSensor system is the first FDA-cleared microarray product based on electrochemical detection of DNA hybridization for personalized medicine applications," says Robin Liu, director of system development, Osmetech Molecular Designs. "It fuses two novel technologies together: electrochemical detection and integrated microfluidic lab-on-a-chip. It offers clinical laboratories the following features that are different from the other platforms: small footprint; medium- to high-throughput capacity with random-access operation; disposable cartridges; simple three-step workflow; rapid test turnaround time of four hours; and high accuracy and specificity. The platform provides a simple method to allow genetic tests in a near patient setting and provides results in less than a few hours." "[Warfarin sensitivity testing] is just the tip of the iceberg. [This product] is like a PC with a basic platform and you can use different cartridges for several genes. One potential application is the detection of cystic fibrosis genes to help determine the likelihood of a child having cystic fibrosis based on the parents' genetics. It's so simple to use, so fast, and the applications are so varied," says Vytas Pazemenas, president and CEO, Aubrey Group Inc. "The journey with Osmetech in the development of the microfluidic recirculating pump in the XT-8 eSensor was an amazing validation of the value that microfluidics brings to these newer, pioneering, multiplexed diagnostic products," says Leanna Levine, president and CEO of Aline Inc. "It also validated our unique approach to microfluidic prototyping using polymer laminate technology."
Warfarin is a commonly prescribed anticoagulant used to treat a variety of disorders; however it has a narrow therapeutic window and response varies widely among individuals. Addition of genetic information, especially for genes CYP2C9 and VKORC1, could potentially improve dosing algorithms. The eSensor® XT-8 is novel technology capable of detecting polymorphisms in these genes. CYP2C9 is the gene that codes for the enzyme that metabolizes warfarin into its inactive metabolites, and mutant *2 and *3 alleles decrease warfarin clearance. VKORC1 codes for an enzyme the recycles reduced vitamin K making it available for use by vitamin K-dependent coagulation factors, and the mutant A allele decreases action. The anticoagulant activity of warfarin is due to inhibition of the VKORC1 enzyme. The results of this study revealed that 47% of the 98 participants had the mutant A allele in the VKORC1 gene and 34% had the mutant *2 or *3 allele for CYP2C9. As a result, these individuals are likely more sensitive to the action of warfarin and/or less effective at clearing the drug. Genetic information could be helpful in determining warfarin dosage but is only one of many factors in warfarin dosing, including age, weight, height, and ethnicity. Validation of the eSensor® Warfarin Sensitivity Test is ongoing at Scott and White Memorial Hospital.
LONDON - (Business Wire) Osmetech plc (OMH.L) (LSE:OMH), the international molecular diagnostics company, announces that its eSensor XT-8 System has been selected by an independent judging panel and editors of R&D Magazine as a recipient of a 2009 R&D 100 Award. This award, also called the “Oscars of Invention”, recognizes the 100 most technologically significant products introduced globally in the past year across all market sectors. Since 1963, the R&D 100 Awards have identified revolutionary technologies newly introduced to the market. Previous award winners include many household names including the automated teller machine, halogen lamp, fax machine, liquid crystal display, printer, and HDTV. This award for Osmetech and comes only one month after the eSensor XT-8 System was named as a gold winner of the 2009 Medical Design Excellence Awards. The FDA-cleared eSensor XT-8 System produces results in less than 30 minutes detecting multiple genetic markers from a prepared patient sample. Using proprietary electro-chemical technology, the self-contained cartridge consumable contains 72 gold-plated electrodes, each acting as independent DNA microsensors on a printed circuit board. The instrument provides an easy-to-use graphical, touch screen interface, a small footprint, requires limited operator training, low maintenance and no instrument calibration. The XT-8 is a complete random access system in which each cartridge slot operates independently supporting the use of a wide variety of tests. The system’s modular and expandable design enables the capacity requirements of high throughput users to be met. Chris Gleeson, Chairman, Osmetech plc, said: "We are delighted that our eSensor XT-8 System has received this prestigious global award. This is further recognition for our innovative, practical and cost-effective platform which is rapidly gaining market acceptance with FDA cleared tests now available for Warfarin Sensitivity and Cystic Fibrosis Genotyping.”
I agree there is a lot of shares in issue, looking at what they do which has been detailed below they could be in for an interesting few weeks/months. Warfarin may be very successful as it will be a drug based fruitflow! or certainly a blood thinning product. for some crazy reason although I am in PXS is the fact that the world likes drugs and the natural alternative always seems to fall short within the medical profession. I don't have access to the plus market, but looking at LSE they had approx 3/4 of a million pounds invested on friday and what looks like 16.35K which was sold at the end of the day for 16.43K. I just think this company merits a good look based on the investment, the big buys could be institutions or more likely big players who either know there is news about to come or in the pipeline. Spirit finder1 is doing a bit of research for me. I have reviewed the RNS's over the last year and they appear to have a forward momentum
Here are the trades on friday 8th. 8-Jan-1016:11:172.19750,000Sell* 2.202.30 16.43k 8-Jan-1016:28:162.2320,000Sell* 2.202.30 446.00 8-Jan-1016:22:292.2073,916Sell* 2.202.30 1,626 8-Jan-1016:22:042.238,338Sell* 2.202.30 185.94 8-Jan-1016:17:232.236,109Sell* 2.202.30 136.23 8-Jan-1016:01:462.20100,000Sell* 2.202.30 2,200 8-Jan-1015:56:342.25100,000 2.202.30 2,250 8-Jan-1015:56:172.2873,916Buy* 2.252.30 1,685 8-Jan-1015:42:432.2530,428Buy* 2.152.30 684.63 8-Jan-1015:17:512.2317,089Buy* 2.152.30 381.08 8-Jan-1014:55:512.2030,000Buy* 2.152.20 660.00 8-Jan-1014:55:392.18750,000Buy* 2.152.20 16.35k 8-Jan-1014:44:532.20250,000Buy* 2.152.20 5,500 8-Jan-1014:35:522.20107,777Buy* 2.102.20 2,371 8-Jan-1014:33:092.2026,571Buy* 2.102.20 584.56 8-Jan-1014:31:572.18250,000Buy* 2.102.20 5,450 8-Jan-1014:29:052.158,500Sell* 2.102.20 182.75 8-Jan-1014:27:272.20100,000Buy* 2.102.20 2,200 8-Jan-1014:19:552.203,350Buy* 2.102. 2073.70 8-Jan-1014:15:592.201,824Buy* 2.102. 2040.13 8-Jan-1014:15:222.18250,000Buy* 2.102.20 5,450 8-Jan-1014:11:142.2090,212Buy* 2.102.20 1,985 8-Jan-1014:07:052.1546,511Sell* 2.102.20 999.99 8-Jan-1013:44:342.1065,708Sell* 2.102.20 1,380 8-Jan-1013:42:132.18100,000Buy* 2.102.20 2,180 8-Jan-1013:40:012.1171,259Sell* 2.102.20 1,504 8-Jan-1013:01:282.11464Sell* 2.102. 209.79 8-Jan-1012:54:042.20500,000Buy* 2.102.20 11.00k 8-Jan-1012:54:182.18229,885Buy* 2.102.20 5,011 8-Jan-1012:52:332.15250,000Buy* 2.002.20 5,375 8-Jan-1012:47:072.013,000Sell* 2.002. 2060.30 8-Jan-1012:39:512.12100,000Buy* 2.002.20 2,120 8-Jan-1012:39:382.12125,000Buy* 2.002.20 2,650 8-Jan-1012:38:382.1250,000Buy* 2.002.20 1,060 8-Jan-1012:37:542.12100,000Buy* 2.002.20 2,120 8-Jan-1012:36:262.12100,000Buy* 2.002.20 2,120 8-Jan-1012:34:302.15100,000Buy* 1.952.20 2,150 8-Jan-1012:24:292.15100,000Buy* 1.952.20 2,150 8-Jan-1012:18:552.005,000,000Buy* 1.952.00 100.00k 8-Jan-1012:09:211.9825,000Buy* 1.952.00 495.00 8-Jan-1012:06:132.0016,211,200Buy* 1.952.00 324.22k 8-Jan-1011:51:201.958,000,000 1.902.00 156.00k 8-Jan-1011:48:401.958,000,000 1.902.00 156.00k 8-Jan-1008:05:182.001,000,000Buy* 1.902.00 20.00k
All good here, I've got 3k in MTA, been waiting for GKP to explode as I was in with 5 at 21, that will release the funds to have a more serious play around, would love to get 10k into MTA. Appreciate the look into this one and time on your behalf, they just had a staggering amount of buys on friday and I think there is something bubbling with this one. Have a good one, I'll check periodically tomorrow, some interesting posts from Jim, managed to lure his mind from MTA on sat,
the 8th which was friday, almost 3/4 of a million £ invested, seems a lot considering the average invest outvest!!
What do you think of the buys and ratio on this company, seems a lot of big buys for such a small company
Thanks for looking at this, I did have a good read through all their RNS's and they seem to be a good company but like most a bit short of cash. The RI has cured that and hopefully with a good couple of years which look very likely they will consolidate. I really like the potential. would you think the good buys were institutional or big pi's
I will put it in the speculative box. and good luck to you with all your venture's
question the timing, although I guess the fact that we have missed the flu bug jab period is probably imaterial as a product is a product
I like the word significant when it comes to company info, especially if it reflects in the SP. So general synopsis from what you have seen would appear to be quite good, and looking at the SP, I would say this could be somewhere near entry level. The buys today could be an indication that things have taken a good move towards this I would suggest